Mostrar el registro sencillo del ítem

dc.contributor.authorAlderson, Mark R
dc.contributor.authorArkwright, Peter D
dc.contributor.authorBai, Xilian
dc.contributor.authorBlack, Steve
dc.contributor.authorBorrow, Ray
dc.contributor.authorCaugant, Dominique A
dc.contributor.authorDinleyici, Ener Cagri
dc.contributor.authorHarrison, Lee H
dc.contributor.authorLucidarme, Jay
dc.contributor.authorMcNamara, Lucy A
dc.contributor.authorMeiring, Susan
dc.contributor.authorSáfadi, Marco A P
dc.contributor.authorShao, Zhujun
dc.contributor.authorStephens, David S
dc.contributor.authorTaha, Muhamed-Kheir
dc.contributor.authorVazquez-Moreno, Julio Alberto 
dc.contributor.authorZhu, Bingqing
dc.contributor.authorGMI collaborators
dc.date.accessioned2022-09-16T13:57:20Z
dc.date.available2022-09-16T13:57:20Z
dc.date.issued2022-03
dc.identifier.citationJ Infect. 2022 Mar;84(3):289-296.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14986
dc.descriptionRevisiónes_ES
dc.description.abstractThis review article incorporates information from the 4th Global Meningococcal Initiative summit meeting. Since the introduction of stringent COVID-19 infection control and lockdown measures globally in 2020, there has been an impact on IMD prevalence, surveillance, and vaccination compliance. Incidence rates and associated mortality fell across various regions during 2020. A reduction in vaccine uptake during 2020 remains a concern globally. In addition, several Neisseria meningitidis clonal complexes, particularly CC4821 and CC11, continue to exhibit resistance to antibiotics, with resistance to ciprofloxacin or beta-lactams mainly linked to modifications of gyrA or penA alleles, respectively. Beta-lactamase acquisition was also reported through horizontal gene transfer (blaROB-1) involving other bacterial species. Despite the challenges over the past year, progress has also been made on meningococcal vaccine development, with several pentavalent (serogroups ABCWY and ACWYX) vaccines currently being studied in late-stage clinical trial programmes.es_ES
dc.description.sponsorshipMedical writing support was funded by Sanofi Pasteur.es_ES
dc.language.isoenges_ES
dc.publisherElsevier es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAntibiotic resistancees_ES
dc.subjectCOVID-19es_ES
dc.subjectCoronaviruses_ES
dc.subjectInvasive meningococcal diseasees_ES
dc.subjectNeisseria meningitidises_ES
dc.subjectPandemices_ES
dc.subjectSerogroupes_ES
dc.subjectSexual transmissiones_ES
dc.subjectVaccinationes_ES
dc.subject.meshCOVID-19es_ES
dc.subject.meshMeningococcal Infections es_ES
dc.subject.meshMeningococcal Vaccines es_ES
dc.subject.meshNeisseria meningitidis es_ES
dc.subject.meshCommunicable Disease Control es_ES
dc.subject.meshHumans es_ES
dc.subject.meshSARS-CoV-2es_ES
dc.subject.meshSerogroup es_ES
dc.titleSurveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative reviewes_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID34838594es_ES
dc.format.volume84es_ES
dc.format.number3es_ES
dc.format.page289-296es_ES
dc.identifier.doi10.1016/j.jinf.2021.11.016es_ES
dc.contributor.funderSafoni Pasteures_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1532-2742es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.jinf.2021.11.016es_ES
dc.identifier.journalThe Journal of infectiones_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional